Categories Annual ReportsCorporate GovernanceDefault CalendarFeatured DocumentsPresentationsProxy Statements Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Title Supernus Announces Resignation of Board Member Supernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy Supernus to Present at Two Investor Conferences in September 2012 Supernus Pharmaceuticals Reports Second Quarter 2012 Financial Results Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer Supernus Provides Update on the Launch of Its Two Epilepsy Products Trokendi XR(TM) and SPN-804 Supernus Receives Tentative Approval of Trokendi XR(TM) From FDA Supernus Pharmaceuticals Reports First Quarter 2012 Financial Results Supernus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering Corporate Governance Guidelines Pagination First page « first Previous page ‹ previous … Page 15 Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Next page next › Last page last »